| Identification | Back Directory | [Name]
EMPA | [CAS]
680590-49-2 | [Synonyms]
EMPA, CID 9981404
N-ETHYL-2-[(6-METHOXYPYRIDIN-3-YL)-(2-METHYLPHENYL)SULFONYLAMINO]-N-(PYRIDIN-3-YLMETHYL)ACETAMIDE
N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)-acetamide
Acetamide, N-ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)- | [Molecular Formula]
C23H26N4O4S | [MOL File]
680590-49-2.mol | [Molecular Weight]
454.54 |
| Chemical Properties | Back Directory | [Boiling point ]
660.7±65.0 °C(Predicted) | [density ]
1.280±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble to 100 mM in DMSO and to 100 mM in ethanol | [form ]
Powder | [pka]
4.77±0.10(Predicted) | [color ]
white to light brown |
| Hazard Information | Back Directory | [Description]
EMPA is an orexin 2 receptor (OX2R) antagonist (Ki = 1.1 nM). It is selective for OX2R over OX1R (Ki = 900 nM). EMPA inhibits orexin-A- and orexin-B-induced calcium mobilization (IC50s = 8.8 and 7.9 nM, respectively) and increases orexin-A- and orexin-B-induced inositol phosphate accumulation (EC50s = 1.1 and 2.4 nM, respectively) in CHO(dHFr-) cells expressing recombinant human OX2R. It reduces spontaneous locomotor activity and orexin-B-induced hyperlocomotion in mice when administered at doses ranging between 10 and 300 mg/kg. | [Uses]
EMPA is a novel high-affinity, selective antagonist for the OX2 receptor. | [storage]
Store at -20°C |
|
|